Organ-on-a-chip devices are sophisticated microfluidic platforms lined with living human cells that emulate the functioning of real organs. These tiny, USB-sized chips can mimic complex biological processes such as lung respiration or blood flow within vessels. By growing human tissue samples—including gut, skin, and brain cells—on these chips, researchers can observe organ-level responses to chemicals in real time, offering substantial improvements over conventional animal models.

Historically, chemical safety assessments have depended heavily on animal subjects, a method criticized for ethical concerns, high costs, and slow turnaround times. OoC technology addresses these issues by providing a human-relevant platform that accelerates the toxicity screening process while reducing expenses. This is particularly crucial as regulatory agencies and industries face increasing pressure to replace animal testing, especially in regions with strict bans on animal use, like in cosmetic product evaluation.

Dr. Han’s team is uniquely focused on chemical toxicity rather than drug safety, leveraging Texas A&M’s renowned toxicology expertise. The lab aims to develop chip systems capable of high-throughput testing that not only detect toxicity but also elucidate the underlying biological mechanisms of harm. Understanding these mechanisms allows for the identification of safer chemical alternatives early in development.

Beyond early screening, these organ chips serve as powerful investigative tools for environmental health researchers, toxicologists, regulators, and manufacturers. By flagging hazardous substances before they reach costly animal experiments or human trials, OoCs streamline the path from discovery to regulatory approval, ultimately enhancing public health protection.

While many laboratories explore organ-on-a-chip models for pharmaceutical purposes, the Texas A&M initiative emphasizes broadening the technology’s application to diverse chemicals, improving predictive accuracy and throughput capacity. The team envisions a future where comprehensive data from these chips will satisfy regulatory demands, reducing reliance on animal models while providing more biologically relevant insights.

Supported by the NIH’s Complement-ARIE program, this research marks a paradigm shift in toxicology testing. It offers a compelling vision of safety evaluation that is faster, more ethical, and better aligned with human biology. As organ-on-a-chip systems evolve, they promise to reshape how science approaches toxicity, fostering innovation and ethical responsibility simultaneously.

Image Credits: Dr. Arum Han

Subject of Research: Organ-on-a-chip technology for chemical toxicity testing
Article Title: Texas A&M Advances Organ-on-a-Chip Systems to Replace Animal Testing in Chemical Safety
News Publication Date: Not provided
Web References: https://engineering.tamu.edu/electrical/profiles/ahan.html; https://www.nih.gov/news-events/news-releases/nih-invests-150-million-human-based-research-reduce-use-animal-models

The core innovation lies in the fabrication of an edible construct designed to exhibit discernible signs of “mind perception,” a psychological dimension that attributes agency and experiential qualities to objects or beings. Typically, mind perception has been investigated through real animals or humanoid robots; however, this study circumvents ethical and experimental limitations by employing edible materials, thereby eliminating welfare concerns while maintaining control over behavioral variables. The edible agent, comprising gelatin, sugar, calcium carbonate, and pure apple juice, materializes as a soft, pliable form with anthropomorphic features including eyes and articulated arms to foster a sense of social presence.

Technically, the agent’s movements are actuated pneumatically via compressed air, causing rhythmic side-to-side swaying synchronous with externally generated audio signals. These audio signals—and the vocalizations embedded within—were crafted to mimic different communicative styles. In the experimental design, two distinct behavioral modes were featured: one where the agent responded with rational, context-appropriate vocalizations to an interlocutor’s statements in Japanese, and another where it emitted emotive, infant-like sounds conveying basic affective states such as joy, fear, anger, and sadness. This dual modality aimed to elicit varied psychological attributions from human observers regarding the edible agent’s perceived mind.

To empirically assess human perception, the researchers conducted an online survey involving 1,094 participants. Methodologically, the participants first viewed a video emphasizing the construct’s edible composition and production process, affirming the agent’s consumability. Subsequently, they observed two separate interaction sequences showcasing the edible agent’s distinct vocal and movement behaviors in response to social stimuli. Participants evaluated the agent across 18 mind-perception items, measuring dimensions related to both cognitive capabilities and emotional experience. Additionally, they anticipated their own reluctance and guilt related to the hypothetical act of consuming the agent, thereby probing the ethical and affective implications of eating entities with apparent minds.

A comprehensive factor analysis distilled mind perception into two principal dimensions: Agency and Experience. Agency encapsulates cognitive faculties such as self-control, moral reasoning, planning, and thought, while Experience comprises sensations and emotions like joy, fear, pain, and rage. Results revealed that the edible agent demonstrating rational vocal responses scored higher on Agency, signifying recognition of intentional and thoughtful capacities. Conversely, the agent exhibiting infantile vocalizations was attributed higher Experience, indicating perceived emotional richness. These findings reveal that subtle differences in vocal expression and behavioral cues can markedly sway the psychological representation of mind in non-living, edible agents.

Intriguingly, despite these modulations in mind perception, the study found no clear correlation between higher mind attribution and participants’ reluctance to eat or feelings of guilt. This suggests a complex dissociation between cognitive-emotional appraisals of mind-like qualities and moral or affective barriers toward food consumption. The authors posit that while vocalizations and behavioral complexity foster mind attribution, other psychological or cultural factors might mediate ethical concerns tied to eating entities ascribed mental states. This nuanced insight challenges simplistic assumptions around anthropomorphism and ethical food choices, highlighting the multifaceted nature of human-food interactions.

Beyond the theoretical contributions, the experimental framework introduced constitutes a versatile tool for dissecting human psychological and ethical responses toward food and food-like entities. Edible agents, by virtue of their controllability in appearance, behavior, and vocal expression, create unprecedented opportunities to simulate and study social interactions within the context of eating. Unlike traditional animal models, these agents bypass ethical dilemmas and experimental variability, enabling rigorous investigation into mind perception, moral considerations, and possibly other cognitive factors influencing dietary acceptance.

Notably, this research also underscores the potential for edible agents to inform the development of alternative food sources and novel food products that intersect with emerging ethical concerns and cultural contexts. As food technology advances toward inclusivity, sustainability, and innovation, understanding how consumers psychologically engage with food items incarnating social properties could inform design strategies that enhance acceptance and reduce cognitive dissonance. This is particularly relevant in the rising landscape of lab-grown meat, insect-based protein, and hybrid food-robot hybrids.

Looking ahead, the research team advocates for future studies incorporating more immersive and ecologically valid conditions, including direct consumption scenarios and autonomous agent behaviors during eating episodes. Such extensions would refine understanding of real-time interactions and emotional dynamics as humans negotiate the boundary between food and social agent. Integrating sensory feedback beyond visual and auditory cues, such as texture and taste, may further enrich the experiential authenticity and affective modulation of edible agents.

The interdisciplinary collaboration among engineers, psychologists, and food scientists reflects the emergent convergence necessary to address complex phenomena at the nexus of technology, cognition, and culture. Key contributors include doctoral student Takuma Shimoyama and former master’s candidate Yuya Kume from The University of Electro-Communications, Assistant Professor Mei Yamagata of Doshisha University, and Associate Professor Hideyuki Takahashi from Otemon Gakuin University. Collectively, their work exemplifies the innovative potential of synthetic biology and interactive robotics in transforming the landscape of food research.

This pioneering work is not only a milestone in understanding mind perception in non-traditional contexts but also paves the way for a new scientific domain dedicated to human perception in human-food interactions. By strategically employing edible materials capable of mimicking behaviors traditionally ascribed to living beings, the study blurs conventional boundaries, challenging both scientific paradigms and societal norms about what it means to “consume” with awareness and ethical reflection. The ramifications extend to multiple fields, including artificial intelligence, human-computer interaction, sensory science, and ethics.

In summary, this landmark study illustrates how innovative material science and psychological inquiry converge to reshape our understanding of food as a dynamic, interactive phenomenon. The concept of edible agents with perceptible minds offers a novel experimental platform for dissecting the cognitive and ethical dimensions that underpin everyday decisions about what we choose to eat. As science and technology continue to evolve, such interdisciplinary endeavors are crucial for anticipating and navigating the future of food, culture, and consciousness.

Subject of Research: People

Article Title: Edible agents with perceptible minds: A psychological study of human perception in human-food interaction

News Publication Date: 22-Jun-2026

Web References: 10.1371/journal.pone.0350612

Image Credits: Yoshihiro Nakata

Keywords: edible agent, mind perception, human-food interaction, psychological study, vocalization, pneumatic actuator, social interaction, ethical eating, gelatin-based robot, experimental psychology

The traditional methods of testing drug safety often involve lengthy and expensive processes, frequently relying on animal models that may not perfectly reflect human responses. These shortcomings have raised ethical concerns while limiting the predictive capability of potential drug candidates. Wang and Rodriguez’s recent study highlights how computational models can address these limitations, providing a reliable alternative that could reduce the reliance on animal testing and enhance the efficiency of drug development.

Cardiomyocyte computational models are meticulously designed simulations that replicate the electrical, mechanical, and biochemical behaviors of real heart cells. By inputting genetic, molecular, and biometric data, researchers can create highly personalized models that represent individual patients or specific disease states. This granularity allows for a more nuanced understanding of how different drugs interact with cardiac cells, paving the way for safer pharmaceuticals tailored to diverse patient populations.

What sets these computational models apart from their predecessors is their capacity for real-time simulation, enabling researchers to tweak variables and observe potential outcomes on the fly. This level of flexibility not only accelerates the research process but also allows for immediate predictive analytics — an invaluable resource for pharma companies navigating the complexities of drug safety testing. With the potential to forecast adverse reactions before they manifest in trials, these models can significantly mitigate risks and ultimately save lives.

Furthermore, the integration of artificial intelligence into these cardiomyocyte models is a game changer. Machine learning algorithms can analyze vast datasets, identifying patterns and correlations that may go unnoticed by human researchers. According to Wang and Rodriguez, this capability could uncover hidden safety liabilities in drug formulations, providing an extra layer of scrutiny that enhances overall patient safety. The evolving relationship between AI and cardiology holds vast potential – an intersection that could reshape how the medical community views drug development.

The implications transcend just drug safety; they hint at a future where personalized medicine becomes the standard rather than the exception. Imagine a scenario where patients receive medications specifically engineered to meet their unique genetic profiles, thus maximizing efficacy while minimizing side effects. The accuracy of cardiomyocyte computational models makes this a conceivable future as researchers continue to refine the technology.

Moreover, the promise of these models extends to educational settings as well. Medical and pharmacological students are now introduced to these computational methods during their training, providing them with the tools necessary to navigate a changing landscape in medicine. The ongoing evolution of cardiomyocyte models not only enhances drug safety but also empowers the next generation of healthcare professionals with skills that reflect modern technological advancements.

Despite these promising developments, there is still a long road ahead. Transitioning to a model where computational models are the norm in drug development requires rigorous validation and acceptance from regulatory bodies like the FDA. Scientists must demonstrate that these models can reliably reproduce human physiological responses before they are widely adopted in the industry. Collaboration between researchers, pharmaceutical companies, and regulators will be crucial in solidifying these models’ positions within the established framework of drug testing.

In conclusion, as Wang and Rodriguez illuminate the scientific community with their insights into cardiomyocyte computational models, the future looks bright. This innovative approach is set to redefine the methodologies used for drug safety, upending age-old practices while introducing efficiencies that ultimately prioritize patient safety. The merging of computational modeling with drug development holds promise not only for the pharmaceutical industry but for the patients who rely on safe and effective treatments. Each step taken in this direction brings the world closer to a more intelligent, responsive healthcare system – one that values both innovation and safety in equal measure.

As research like this unfolds, it lays the foundation for breakthroughs that go beyond the laboratory. Society stands on the threshold of significant advancements in health outcomes driven by technology. Efforts to enhance drug safety through computational cardiomyocyte models are emblematic of a broader movement towards data-driven healthcare solutions, highlighting the necessity for continued investment in research and development as we leap into the future.

Research in the field will likely evolve rapidly, continuously articulating new questions and challenges. Therefore, staying abreast of these developments will be critical for anyone engaged in the healthcare and pharmaceutical sectors. By leveraging the advancements offered by computational modeling and artificial intelligence, the medical community can ensure that safety and efficacy remain at the forefront of drug development, ultimately yielding better outcomes for patients globally.

Subject of Research: Cardiomyocyte Computational Models for Drug Safety

Article Title: The promise of cardiomyocyte computational models for drug safety

Article References:

Wang, L., Rodriguez, B. The promise of cardiomyocyte computational models for drug safety. Military Med Res 12, 88 (2025). https://doi.org/10.1186/s40779-025-00675-3

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s40779-025-00675-3

Keywords: Cardiomyocytes, Computational Models, Drug Safety, Personalized Medicine, Artificial Intelligence, Pharmacology, Drug Development, Machine Learning, Healthcare Technology, Innovation.

Published in the prestigious journal Advanced Science, this innovation stems from meticulous engineering within UC Irvine’s Samueli School of Engineering. The researchers meticulously crafted a miniaturized, approximately 5-by-10-millimeter colon replica that embodies vital anatomical elements of the human colon — including its distinctive liminal curvature, a sophisticated multilayered cellular architecture, and the spontaneous formation of cryptlike invaginations universally recognized as crucial to colon function and cancer biology.

Rahim Esfandyar-pour, assistant professor of electrical engineering and computer science at UC Irvine and senior author of the study, emphasizes that the precise three-dimensional topology of the 3D-IVM-HC model is central to sustaining authentic cellular dynamics. He elucidates that this structural realism enables the recreation of microenvironmental cues governing cell behavior in a manner unattainable by conventional flat cultures or even some animal models. This breakthrough lays the groundwork for enhanced drug screening fidelity and personalized therapeutic testing that can predict clinical patient outcomes with markedly improved accuracy.

Esfandyar-pour cites fundamental limitations with existing preclinical models, notably that roughly 50% of toxicological results derived from rodent experiments fail to translate effectively to human clinical scenarios. He highlights that traditional animal models insufficiently recapitulate key hallmarks of human tumor biology, posing formidable challenges to early-phase drug development. In addition to biological incongruities, he notes the staggering financial overhead of these animal-based studies—which can accumulate to multimillion-dollar expenses over multiple years—undermining scalability and responsiveness in urgent therapeutic contexts.

The 3D-IVM-HC model leverages a sophisticated bioelectronic integration to bridge these gaps, yielding a sustainable, ethical, and human-relevant experimental platform. Its core structure is fabricated from a biocompatible scaffold composed of gelatin methacrylate and alginate, materials selected for their ability to emulate the soft, pliable nature of colon tissue. This scaffold provides a supportive matrix upon which human epithelial colon cells are cultured on the interior surface, mirroring the in vivo luminal lining, while fibroblasts embedded in the outer scaffold layer recreate the mucosal microenvironment that plays a critical role in tissue homeostasis and disease progression.

This meticulously engineered cellular configuration fosters enhanced cell-to-cell communication pathways, resulting in quadruple the cell density observed in conventional two-dimensional cultures. This dense, dynamic cellular assembly not only promotes robust barrier integrity, akin to the human colon’s protective function, but also establishes a more physiologically pertinent milieu for testing the complex interplay between cancer therapeutics and tumor cells.

Of profound significance, the 3D-IVM-HC model demonstrates superior performance over existing culture systems in drug efficacy testing. When subjected to 5-fluorouracil—a widely administered chemotherapy agent—colon cancer cells within the model manifested striking resistance, necessitating drug concentrations approximately tenfold higher to achieve cytotoxic effects equivalent to those observed in standard petri dish cultures. This resistance parallels the clinical reality faced in oncology, underscoring the model’s unparalleled ability to recapitulate human tumor drug response and thus its potential to improve therapeutic screening and dosing paradigms.

Beyond standard pharmacological evaluation, the model is envisioned as a cornerstone for truly personalized medicine. With the capacity to cultivate patient-derived cells obtained from tumor biopsies, it becomes feasible to generate individualized mini-colons that can rapidly assess and predict therapeutic efficacy on a patient-specific basis. This approach opens transformative avenues for tailoring treatment regimens that maximize clinical benefits while minimizing adverse effects.

Remarkably, the development and maturation of the 3D-IVM-HC model require approximately two weeks, with subsequent drug testing completed within days—a timeline drastically reduced compared to protracted animal studies. This accelerated process not only enhances throughput but simultaneously lowers research costs and ethical concerns, heralding a new era where preclinical trials become more responsive to patient needs and research demands.

Esfandyar-pour asserts that this platform stands to deepen mechanistic insights into colorectal cancer pathogenesis, facilitating more accurate predictions of therapeutic responses, and expediting the pipeline for high-throughput drug discovery. The integration of bioelectronics also allows for real-time monitoring and manipulation of disease states within the model, deepening the potential for dynamic experimental control and optimization.

From an implementation perspective, hospitals and research laboratories could adopt this model as a frontline tool for ethical, efficient, and precise preclinical testing. If widely embraced, it could dismantle long-standing bottlenecks in oncology drug development, yielding faster, safer, and more affordable pathways from bench to bedside improvement in clinical outcomes globally.

In sum, the UC Irvine team’s bold leap towards bridging biology and engineering sets a new paradigm for cancer research tools. By faithfully reproducing the colon’s complex structural and functional features on a micro-scale, the 3D-IVM-HC model stands as a beacon for nonanimal, patient-aligned experimental models, promising enhanced translatability, reduced animal use, and accelerated discovery of life-saving therapies in colorectal cancer and beyond.

Subject of Research: Not applicable
Article Title: Development of a 3D Human Colon Model Along with Bioelectronics for the Induction and Monitoring of Diseases
News Publication Date: 15-Oct-2025
Web References:

• https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202506377
• http://dx.doi.org/10.1002/advs.202506377
  Keywords: Colorectal cancer, Biochemical engineering

The remarkable ability of hydrogels to hold large amounts of water makes them ideal candidates for creating skin-like structures conducive to cell survival and growth. These substances are designed to foster an environment that not only supports living skin cells but also encourages their proliferation. The research team has made substantial progress in developing hydrogel formulations that can be produced via 3D printing, thus establishing a reliable starting point for producing stable and functional structures that can stand up to real-world conditions and stressors.

Karin Stana Kleinschek, a lead researcher from the Institute of Chemistry and Technology of Biobased Systems, notes that the hydrogels must meet several criteria to be effective. They must interact flawlessly with living cells and possess characteristics that allow for cell survival and growth over extended periods. The integration of living cells into the printed hydrogels represents a monumental step forward, allowing for the realistic modeling of skin tissues that can serve as platforms for future cosmetic testing. The research team is working on cross-linking methods to stabilize the printed structures, aiming for processes that do not rely on cytotoxic chemicals, ensuring that the product remains suitable for biological interactions.

A pivotal goal of this research is to create a skin imitation that can survive for two to three weeks in cell cultures. This duration is critical for the development of skin tissue, allowing it to be tested for resistance and toxicity before advancing to more complex experiments. Only when the skin cells demonstrate longevity and biological activity in tests can these engineered materials be endorsed as viable substitutes for animal testing. The researchers have noted that any skin imitations produced successfully will then undergo various cosmetic tests, providing insights that could lead to safer cosmetic formulations.

The preliminary results have been promising. The experiments conducted so far indicate that the 3D-printed hydrogels are not only mechanically stable but also non-cytotoxic. These findings mark a significant milestone in the research agenda of both TU Graz and VIT, highlighting the extensive manufacturing capabilities of their collaborations. The combined expertise in material research from TU Graz and molecular biology from VIT has proven effective, marrying the strengths of both institutions to push forward the potential for creating effective substitutes for animal testing.

In the field of tissue engineering, the implications of creating hydrogels that accurately replicate human skin extend far beyond cosmetics. They open up avenues for the development of other medical applications, including drug testing, wound healing, and regenerative medicine. By understanding how nanoparticles and other substances interact with this artificial skin, researchers can better determine the safety and efficacy of numerous products intended for human use.

The next phase of this research will involve utilizing the developed skin imitations to conduct tests on various nanoparticles found in sunblock and other cosmetics. These particles, often crucial for improving the effectiveness of sun protection, need to be examined thoroughly to ensure they do not pose health risks when absorbed by human skin. By employing the 3D-printed skin constructs, the researchers aim to provide a more ethical and reliable framework for conducting toxicity studies, paving the way for innovative strategies that prioritize human safety while minimizing animal usage in scientific research.

The long-term vision behind this project is not just to create a transient solution to comply with ethical guidelines regarding animal testing; rather, it signifies a potential paradigm shift in how cosmetic products are researched and tested. If successful, this technology could fundamentally change regulatory frameworks worldwide, offering an ethically responsible alternative that aligns with modern scientific and societal values. The implications of such advancements could resonate through various industries, particularly those heavily scrutinized for their testing practices.

Furthermore, the collaboration seeks to leverage 3D printing technology’s unique capabilities to produce customized and adaptable hydrogel formulations that can be tailored for specific research contexts. This adaptability represents a substantial advantage over current static models, enabling researchers to refine their approaches as new challenges or questions emerge in the ever-evolving landscape of cosmetic safety and efficacy. As the push for transparency and consumer safety continues to grow, innovations like these will likely usher in a new era of accountability within the cosmetics industry.

Ultimately, the work of Graz University of Technology and the Vellore Institute of Technology serves as a beacon of progress in the scientific community, showcasing the potential for collaborative research to confront ethical dilemmas in modern science. This groundbreaking initiative redefines the parameters of safety testing, illuminating a path forward that prioritizes both consumer safety and animal welfare. As the team continues to refine their methodologies and validate their findings, the hope is that their innovations will not only revolutionize cosmetic testing but will also inspire further research aimed at reimagining sustainability and ethics in science.

As researchers await further validation and refinement of their skin imitations, the excitement about potential breakthroughs continues to build. The successful deployment of these technologies could set the stage for a critical transformation in research practices, enabling safer, more effective products while paving the way for a future that embraces ethical scientific exploration.

With these advancements, scientists not only hope to satisfy regulatory requirements but also aim to ensure that consumers can trust the safety profiles of the cosmetic products they choose to use. This is a pivotal moment in the intersection of technology and biology, establishing a new benchmark for the field of cosmetics and paving the way for innovations that prioritize human health and ethical scientific practices.

Subject of Research: Cells
Article Title: Protocol for the fabrication of self-standing (nano)cellulose-based 3D scaffolds for tissue engineering
News Publication Date: 21-Mar-2025
Web References: http://dx.doi.org/10.1016/j.xpro.2024.103583
References: N/A
Image Credits: Credit: Manisha Sonthalia – Vellore Institute of Technology

Keywords

3D printing, hydrogels, skin imitation, tissue engineering, animal testing, cosmetics, non-cytotoxic, nanoparticles, bioengineering, consumer safety, ethical research, dermatotoxicology.